Clinical Trial Update: Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating subretinal ATSN-101 for Leber congenital amaurosis caused by biallelic GUCY2D mutations is currently active but not recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leber Congenital Amaurosis

Drugs mentioned

• ATSN-101

Snippet

Sponsor: Atsena Therapeutics Inc. | Conditions: Leber Congenital Amaurosis, LCA | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING